Please wait while the formulary information is being retrieved.
NUBEQA (darolutamide)
- Non-metastatic castration-resistant prostate cancer
300 mg tablet
- 2 tablets (600 mg) by oral route 2 times per day
Non-metastatic castration-resistant prostate cancer
- 1 tablet (300 mg) by oral route 2 times per day
- 2 tablets (600 mg) by oral route 2 times per day
- natalizumab
- Tysabri
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Disease of liver
- Pregnancy
Severe
Moderate
- None
NUBEQA (darolutamide)
- Non-metastatic castration-resistant prostate cancer
- Neutropenic disorder
- Fatigue
- Hyperbilirubinemia
- Increased aspartate transaminase
- Pain
- Skin rash
More Frequent
Severe
Less Severe
- Myocardial ischemia
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
Darolutamide
No pediatric safety and efficacy. Indicated only for metastatic prostate cancer.
- 1 Day – 18 Years
- No pediatric safety and efficacy. Indicated only for metastatic prostate cancer.
Management or Monitoring Precaution
None
Darolutamide
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Darolutamide
None
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Non-metastatic castration-resistant prostate cancer | |
C61 | Malignant neoplasm of prostate |
0-9 | A-Z |
---|---|
C61 | Malignant neoplasm of prostate |
Formulary Reference Tool